ADORA2A and juvenile Huntington disease: Together, these results raise the intriguing hypothesis that SMF can reproduce the effects of a promising class of non-dopaminergic PD drugs in a non-invasive manner and, more broadly, hold potential for ameliorating additional neurological disorders such as Alzheimer's and Huntington's diseases through modulation of A2AR [64]–[66].